DENVER, Colo., 07 August, 2024 (247marketnews.com) – (NASDAQ:ADTX) are discussed in this article.
Aditxt, Inc. (NASDAQ:ADTX) has captured significant market attention with its common stock experiencing a remarkable 43.73% surge in the pre-market trading session, reaching $1.389 from its previous close of $0.997. This performance is supported by a substantial trading volume of 1.4 million shares, reflecting strong investor confidence and a potential upward trajectory for the biotech company. Technical indicators point to a breakout pattern, underscoring the opportunity for potential gains as Aditxt showcases formidable strength in the market.
Further bolstering the company’s prospects, Aditxt’s subsidiary, Pearsanta, Inc., has submitted a proposal to the Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP). This proposal aims to validate a novel early detection assay for ovarian cancer utilizing Pearsanta’s proprietary Mitomic® Technology. Ovarian cancer, characterized by over 324,603 new cases annually worldwide, suffers from a lack of sensitive early detection methods, hampering effective treatment and outcomes.
Pearsanta’s innovative approach employs mitochondrial DNA (mtDNA) through non-invasive, blood-based liquid biopsies to identify specific mutations that serve as biomarkers for several conditions, including ovarian cancer. The Mitomic Ovarian Test (MOT) is devised to detect these mtDNA mutations in the early stages of ovarian cancer, which could significantly improve patient prognosis.
Chris Mitton, President of Pearsanta, emphasized the importance of this proposal, noting its potential to revolutionize early cancer detection. This proprietary technology enables swift, non-invasive, and precise blood tests, ultimately enhancing treatment outcomes and saving lives. Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt, highlighted the MOT’s potential to address a critical unmet need in women’s health, aiming to transform diagnostic methods and improve global survival rates.
The proposal includes a prospective cohort study involving 100 ovarian cancer patients and 200 controls to demonstrate MOT’s diagnostic accuracy. If successful, MOT could become a pivotal tool in early ovarian cancer detection. Aditxt and Pearsanta remain committed to pioneering advancements in immune health, precision health, public health, and women’s health, tackling some of today’s most pressing health challenges.
For further details, visit www.aditxt.com. Follow Aditxt on LinkedIn and Facebook.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com